Autopsy report · NCT00940095
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
Cause of deathFutility
“Lack of efficacy data from the Phase 3 clinical study (AC-054-301; CONSCIOUS-2)”
Life of this trial
- Ran for about 1 year 6 months before it stopped.
- 577 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Sponsor type
- Industry
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Clazosentan 5 m/h; Clazosentan 15 mg/h; Placebo
- Participants
- 577
- Sites
- 145
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany and more
Trials that died the same way
- Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
“The study was terminated based on review of Phase 2 efficacy data” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - A Pilot Study of Candesartan as a Treatment for Cocaine Dependence
“Results of interim efficacy analysis showed results were not promising.” - A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
“The study was early terminated due to lack of efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.